[Pubmed] Real-World Clinical Outcomes and Corticosteroid Tapering in Telitacicept-Based Therapy for Ocular Myasthenia Gr

[RSS-Bot]

Brain Behav. 2026 Oct;16(10):e71816. doi: 10.1002/brb3.71816.

ABSTRACT

INTRODUCTION: Ocular myasthenia gravis (OMG) is an autoantibody-mediated disease characterized by extraocular muscle weakness. Telitacicept has shown potential in treating autoimmune diseases, but its efficacy and corticosteroid-tapering outcomes in OMG remain unexamined.

METHODS: This retrospective, multicenter study evaluated the efficacy and corticosteroid-tapering outcomes of telitacicept in 19 OMG patients (11 with refractory OMG and eight with newly/reinitiated treatment OMG). The primary endpoint was the proportion of patients achieving minimal symptom expression (MSE) within 6 months. Secondary endpoints included changes in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores and reductions in daily prednisone dosage, cumulative response rate (CRR), and short-term tolerability.

RESULTS: Following 6 months of telitacicept treatment, 68.42% of the overall cohort achieved MSE, with the median MG-ADL score significantly decreasing from 3.00 to 0.00 (p < 0.0001). Daily prednisone dosage substantially decreased: the median daily prednisone dose fell from 20.00 to 5.00 mg (p < 0.0001), and 84.21% of patients received prednisone at ≤5 mg/day at month 6. All patients met the predefined initial response criterion within 5 weeks. The refractory and newly/reinitiated treatment groups achieved final MSE rates of 72.7% and 62.5%, respectively, and both groups showed significant reductions in prednisone dependence. This cohort had no serious adverse events.

CONCLUSION: In this exploratory cohort, telitacicept-based therapy may represent a promising option for OMG, with favorable clinical outcomes, substantial prednisone dose reduction, and acceptable short-term tolerability in patients with different prior treatment histories. Further prospective controlled studies are warranted.

PMID:42850995 | DOI:10.1002/brb3.71816


Source: https://pubmed.ncbi.nlm.nih.gov/4285099 ... 2&v=2.20.1